Posted by This chapter offers a detailed overview of the structural features, different types, and chemical modifications of CDs and their derivatives, including hydroxypropyl-β-CD (HP-β-CD) and sulfobutyl ether-β-CD (SBE-β-CD). It discusses their use across various drug delivery methods such as oral, parenteral, ocular, nasal, transdermal, and rectal routes. Special focus is given to clinically approved CD-based formulations, like Captisol®-enabled products and Veklury®, which have improved therapeutic effectiveness and patient safety. The chapter also examines current regulatory views, toxicological issues, especially nephrotoxicity linked to β-CDs, and the evolving patent landscape related to CD-based biomaterials.
Buschmann, H., Holenz, J., Müller, C., Shevalkar, G., Tiwari, S., Bari, D., Pardeshi, C. and Kamble, S. (2026). Cyclodextrin-Based Formulations to Improve Solubility of Poorly Soluble Drugs. In Drug Development Approaches for Poorly Soluble Compounds (eds Y. Bachhav, H. Buschmann, J. Holenz and C. Müller). https://doi.org/10.1002/9783527850761.ch9